When patients leave their doctor's office clutching a new prescription, many head straight to Google or Reddit for answers. XO Life, a Munich healthtech startup, is betting pharmaceutical companies would prefer those searches happen on a platform they control—and can learn from.
The company just closed a €4 million funding round in April, led by Paris-based Fil Rouge Capital. Existing backers Sandwater, Grazia Equity, VI Partners, and Bayern Kapital all returned for the round, which brings XO Life's total raised to around €13 million according to the company. That's a notable haul for a company operating in the decidedly unsexy space of patient data collection, though perhaps less surprising given the regulatory tailwinds now pushing pharma companies toward real-world evidence.
XO Life's flagship product, brite—rechristened from the clunkier "ImpactMonitor" early last year—functions as what the company calls a meta-platform for digital therapy support. In plain terms, it's a white-labeled interface that lets drug makers push educational content to patients, track how they're actually faring on medication (not just in controlled trials), and hoover up the patient-reported outcomes that regulators increasingly want to see.
The pitch to pharma is straightforward, if a bit self-serving: Better we mediate the patient relationship than TikTok.
Building Infrastructure for a Data-Hungry Industry
Co-founder and CEO Friderike Bruchmann, who holds a doctorate and co-leads the company alongside engineer Johannes Bachhuber, started XO Life—originally Medikura Digital Health—with a seed round of more than €2 million in early 2022. Back then, the concept was to standardize patient-reported outcomes across therapeutic areas. The company has since pivoted toward becoming the rails pharmaceutical companies use to deliver therapy support programs at scale.
The business model reveals itself through a string of recent partnerships. Vertex Pharmaceuticals signed on last July to offer cystic fibrosis patients digital support through brite. That same month, German generic-drug maker biosyn Arzneimittel joined, followed by AAA-Pharma in November. The companies are essentially outsourcing patient engagement to XO Life, which aggregates anonymized data across multiple drugs and diseases.
Pharma's growing appetite for such platforms isn't accidental. The European Medicines Agency has been formalizing its approach to real-world evidence coordination, with framework updates continuing through 2024 and 2025. Across the Atlantic, the FDA finalized patient-focused drug development guidance in April 2023, explicitly calling for clinical outcome assessments rooted in patient experience. When regulators start asking for new kinds of data, infrastructure providers tend to multiply.
XO Life has also cultivated academic credibility, partnering with institutions like the Charité PROMIS Institute in Berlin, which specializes in standardized patient outcomes measurement. These affiliations lend the platform a patina of clinical rigor that pure consumer health apps often lack.
Scaling Problems, Series A Ambitions
The fresh €4 million—coming roughly 20 months after a €7 million round in August 2023—is earmarked for European expansion and automation. XO Life wants to smooth the onboarding process for pharmaceutical partners, a telling priority. Enterprise sales in healthcare move slowly; anything that accelerates contract-to-launch timelines can mean the difference between landing a deal and losing it to a competitor.
The company currently employs somewhere between 11 and 50 people, based on available workforce signals. That's small for a platform with multinational pharma clients, which suggests either lean operations or early-stage growing pains. Management framed this round as a bridge to a Series A, though no timeline was specified.
One wrinkle: XO Life is threading a tricky needle. Patients generally don't wake up excited to share health data with drug companies, even if that data might improve future treatments. The platform's success depends on pharma convincing patients the trade-off is worth it—free educational resources and symptom tracking in exchange for participation in what is, functionally, ongoing post-market surveillance.
That's a harder sell in Europe, where data privacy concerns run hotter than in the United States, and where patients have grown wary of digital health promises that don't always deliver. Whether brite can overcome that skepticism at scale remains an open question.
The Real-World Evidence Arms Race
For now, XO Life is riding a genuine shift in how drugs get developed and monitored. Randomized controlled trials remain the gold standard for approval, but they're expensive, slow, and often exclude the messy reality of patients with multiple conditions. Real-world evidence—gathered from actual prescriptions written in actual clinics—fills some of those gaps. It also helps pharma demonstrate value to payers, who increasingly demand proof that drugs work outside the rarefied air of a clinical trial.
Platforms like brite essentially industrialize that evidence collection. Instead of each pharma company building bespoke patient portals for every drug, they plug into XO Life's infrastructure and get standardized data streams. It's the SaaS-ification of pharmacovigilance, and it's arriving just as regulators are starting to require it.
Whether that's enough to justify a Series A valuation in a market that's grown choosier about healthtech deals is another matter. But for a Munich startup that raised its first institutional funding a few years ago, around €13 million in the bank and a handful of Big Pharma partnerships isn't a bad place to be. Assuming, of course, that patients keep opting in.
